Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 15 entries
Sorted by: Best Match Show Resources per page
Effect of Web-Based Versus Paper-Based Questionnaires and Follow-Up Strategies on Participation Rates of Dutch Childhood Cancer Survivors: A Randomized Controlled Trial.

JMIR cancer

Kilsdonk E, van Dulmen-den Broeder E, van der Pal HJ, Hollema N, Kremer LC, van den Heuvel-Eibrink MM, van Leeuwen FE, Jaspers MW, van den Berg MH.
PMID: 28410161
JMIR Cancer. 2015 Nov 24;1(2):e11. doi: 10.2196/cancer.3905.

BACKGROUND: Questionnaires are widely used in survey research, especially in cohort studies. However, participation in questionnaire studies has been declining over the past decades. Because high participation rates are needed to limit the risk of selection bias and produce...

Cite
Kilsdonk E, van Dulmen-den Broeder E, van der Pal HJ, et al. Effect of Web-Based Versus Paper-Based Questionnaires and Follow-Up Strategies on Participation Rates of Dutch Childhood Cancer Survivors: A Randomized Controlled Trial. JMIR Cancer. 2015;1(2):e11doi: 10.2196/cancer.3905.
Kilsdonk, E., van Dulmen-den Broeder, E., van der Pal, H. J., Hollema, N., Kremer, L. C., van den Heuvel-Eibrink, M. M., van Leeuwen, F. E., Jaspers, M. W., & van den Berg, M. H. (2015). Effect of Web-Based Versus Paper-Based Questionnaires and Follow-Up Strategies on Participation Rates of Dutch Childhood Cancer Survivors: A Randomized Controlled Trial. JMIR cancer, 1(2), e11. https://doi.org/10.2196/cancer.3905
Kilsdonk, Ellen, et al. "Effect of Web-Based Versus Paper-Based Questionnaires and Follow-Up Strategies on Participation Rates of Dutch Childhood Cancer Survivors: A Randomized Controlled Trial." JMIR cancer vol. 1,2 (2015): e11. doi: https://doi.org/10.2196/cancer.3905
Kilsdonk E, van Dulmen-den Broeder E, van der Pal HJ, Hollema N, Kremer LC, van den Heuvel-Eibrink MM, van Leeuwen FE, Jaspers MW, van den Berg MH. Effect of Web-Based Versus Paper-Based Questionnaires and Follow-Up Strategies on Participation Rates of Dutch Childhood Cancer Survivors: A Randomized Controlled Trial. JMIR Cancer. 2015 Nov 24;1(2):e11. doi: 10.2196/cancer.3905. PMID: 28410161; PMCID: PMC5367669.
Copy Download .nbib Format: NLM
Cancer Survivorship Care: Person Centered Care in a Multidisciplinary Shared Care Model.

International journal of integrated care

Loonen JJ, Blijlevens NM, Prins J, Dona DJ, Den Hartogh J, Senden T, van Dulmen-Den Broeder E, van der Velden K, Hermens RP.
PMID: 29588641
Int J Integr Care. 2018 Jan 16;18(1):4. doi: 10.5334/ijic.3046.

Survivors of childhood and adult-onset cancer are at lifelong risk for the development of late effects of treatment that can lead to serious morbidity and premature mortality. Regular long-term follow-up aiming for prevention, early detection and intervention of late...

Cite
Loonen JJ, Blijlevens NM, Prins J, et al. Cancer Survivorship Care: Person Centered Care in a Multidisciplinary Shared Care Model. Int J Integr Care. 2018;18(1):4doi: 10.5334/ijic.3046.
Loonen, J. J., Blijlevens, N. M., Prins, J., Dona, D. J., Den Hartogh, J., Senden, T., van Dulmen-Den Broeder, E., van der Velden, K., & Hermens, R. P. (2018). Cancer Survivorship Care: Person Centered Care in a Multidisciplinary Shared Care Model. International journal of integrated care, 18(1), 4. https://doi.org/10.5334/ijic.3046
Loonen, Jacqueline J, et al. "Cancer Survivorship Care: Person Centered Care in a Multidisciplinary Shared Care Model." International journal of integrated care vol. 18,1 (2018): 4. doi: https://doi.org/10.5334/ijic.3046
Loonen JJ, Blijlevens NM, Prins J, Dona DJ, Den Hartogh J, Senden T, van Dulmen-Den Broeder E, van der Velden K, Hermens RP. Cancer Survivorship Care: Person Centered Care in a Multidisciplinary Shared Care Model. Int J Integr Care. 2018 Jan 16;18(1):4. doi: 10.5334/ijic.3046. PMID: 29588641; PMCID: PMC5854087.
Copy Download .nbib Format: NLM
Long-Term Effects of Childhood Cancer Treatment on Dentition and Oral Health: A Dentist Survey Study from the DCCSS LATER 2 Study.

Cancers

Stolze J, Vlaanderen KCE, Holtbach FCED, Teepen JC, Kremer LCM, Loonen JJ, van Dulmen-den Broeder E, Heuvel-Eibrink MMVD, Pal HJHV, Versluys B, van der Heiden-van der Loo M, Louwerens M, Raber-Durlacher JE, Bresters D, Brand HS.
PMID: 34771429
Cancers (Basel). 2021 Oct 20;13(21). doi: 10.3390/cancers13215264.

OBJECTIVES: The aim of this study was to identify the prevalence of and independent risk factors for long-term effects of childhood cancer treatment on the dentition and oral health in childhood cancer survivors (CCSs).METHODS: This cross-sectional study is part...

Cite
Stolze J, Vlaanderen KCE, Holtbach FCED, et al. Long-Term Effects of Childhood Cancer Treatment on Dentition and Oral Health: A Dentist Survey Study from the DCCSS LATER 2 Study. Cancers (Basel). 2021;13(21)doi: 10.3390/cancers13215264.
Stolze, J., Vlaanderen, K. C. E., Holtbach, F. C. E. D., Teepen, J. C., Kremer, L. C. M., Loonen, J. J., van Dulmen-den Broeder, E., Heuvel-Eibrink, M. M. V. D., Pal, H. J. H. V., Versluys, B., van der Heiden-van der Loo, M., Louwerens, M., Raber-Durlacher, J. E., Bresters, D., & Brand, H. S. (2021). Long-Term Effects of Childhood Cancer Treatment on Dentition and Oral Health: A Dentist Survey Study from the DCCSS LATER 2 Study. Cancers, 13(21), . https://doi.org/10.3390/cancers13215264
Stolze, Juliette, et al. "Long-Term Effects of Childhood Cancer Treatment on Dentition and Oral Health: A Dentist Survey Study from the DCCSS LATER 2 Study." Cancers vol. 13,21 (2021). doi: https://doi.org/10.3390/cancers13215264
Stolze J, Vlaanderen KCE, Holtbach FCED, Teepen JC, Kremer LCM, Loonen JJ, van Dulmen-den Broeder E, Heuvel-Eibrink MMVD, Pal HJHV, Versluys B, van der Heiden-van der Loo M, Louwerens M, Raber-Durlacher JE, Bresters D, Brand HS. Long-Term Effects of Childhood Cancer Treatment on Dentition and Oral Health: A Dentist Survey Study from the DCCSS LATER 2 Study. Cancers (Basel). 2021 Oct 20;13(21). doi: 10.3390/cancers13215264. PMID: 34771429; PMCID: PMC8582458.
Copy Download .nbib Format: NLM
Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study.

Neuro-oncology advances

Meijer AJM, Fiocco MF, Janssens GO, Clemens E, Tissing WJE, Loonen JJ, van Dulmen-den Broeder E, de Vries ACH, Bresters D, Versluys B, Ronckers CM, Kremer LCM, van der Pal HJ, Neggers SJCMM, van der Heiden-van der Loo M, Stokroos RJ, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM.
PMID: 33196041
Neurooncol Adv. 2020 Sep 15;2(1):vdaa122. doi: 10.1093/noajnl/vdaa122. eCollection 2020.

BACKGROUND: Tinnitus is a serious late effect of childhood cancer treatment. The aim of this study was to determine the occurrence and risk factors for tinnitus in a national cohort of childhood cancer survivors (CCS).METHODS: Data were collected within...

Cite
Meijer AJM, Fiocco MF, Janssens GO, et al. Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study. Neurooncol Adv. 2020;2(1):vdaa122doi: 10.1093/noajnl/vdaa122.
Meijer, A. J. M., Fiocco, M. F., Janssens, G. O., Clemens, E., Tissing, W. J. E., Loonen, J. J., van Dulmen-den Broeder, E., de Vries, A. C. H., Bresters, D., Versluys, B., Ronckers, C. M., Kremer, L. C. M., van der Pal, H. J., Neggers, S. J. C. M. M., van der Heiden-van der Loo, M., Stokroos, R. J., Hoetink, A. E., van Grotel, M., & van den Heuvel-Eibrink, M. M. (2020). Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study. Neuro-oncology advances, 2(1), vdaa122. https://doi.org/10.1093/noajnl/vdaa122
Meijer, Annelot J M, et al. "Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study." Neuro-oncology advances vol. 2,1 (2020): vdaa122. doi: https://doi.org/10.1093/noajnl/vdaa122
Meijer AJM, Fiocco MF, Janssens GO, Clemens E, Tissing WJE, Loonen JJ, van Dulmen-den Broeder E, de Vries ACH, Bresters D, Versluys B, Ronckers CM, Kremer LCM, van der Pal HJ, Neggers SJCMM, van der Heiden-van der Loo M, Stokroos RJ, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM. Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study. Neurooncol Adv. 2020 Sep 15;2(1):vdaa122. doi: 10.1093/noajnl/vdaa122. eCollection 2020. PMID: 33196041; PMCID: PMC7648591.
Copy Download .nbib Format: NLM
Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset.

Data in brief

Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, Binder H, Mayer B, von dem Knesebeck A, Byrne J, van Dulmen-den Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Spix C, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, van der Kooi AF, Kremer LC, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni CE, Ansari M, Kompis M, van der Pal HJ, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing WJE, Beck JD, Elsner S, Am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink MM, Zolk O.
PMID: 32939381
Data Brief. 2020 Aug 24;32:106227. doi: 10.1016/j.dib.2020.106227. eCollection 2020 Oct.

Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (

Cite
Langer T, Clemens E, Broer L, et al. Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data Brief. 2020;32:106227doi: 10.1016/j.dib.2020.106227.
Langer, T., Clemens, E., Broer, L., Maier, L., Uitterlinden, A. G., de Vries, A. C. H., van Grotel, M., Pluijm, S. F. M., Binder, H., Mayer, B., von dem Knesebeck, A., Byrne, J., van Dulmen-den Broeder, E., Crocco, M., Grabow, D., Kaatsch, P., Kaiser, M., Spix, C., Kenborg, L., Winther, J. F., Rechnitzer, C., Hasle, H., Kepak, T., van der Kooi, A. F., Kremer, L. C., Kruseova, J., Bielack, S., Sorg, B., Hecker-Nolting, S., Kuehni, C. E., Ansari, M., Kompis, M., van der Pal, H. J., Parfitt, R., Deuster, D., Matulat, P., Tillmanns, A., Tissing, W. J. E., Beck, J. D., Elsner, S., Am Zehnhoff-Dinnesen, A., van den Heuvel-Eibrink, M. M., Zolk, O. (2020). Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data in brief, 32106227. https://doi.org/10.1016/j.dib.2020.106227
Langer, Thorsten, et al. "Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset." Data in brief vol. 32 (2020): 106227. doi: https://doi.org/10.1016/j.dib.2020.106227
Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, Binder H, Mayer B, von dem Knesebeck A, Byrne J, van Dulmen-den Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Spix C, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, van der Kooi AF, Kremer LC, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni CE, Ansari M, Kompis M, van der Pal HJ, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing WJE, Beck JD, Elsner S, Am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink MM, Zolk O. Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data Brief. 2020 Aug 24;32:106227. doi: 10.1016/j.dib.2020.106227. eCollection 2020 Oct. PMID: 32939381; PMCID: PMC7477761.
Copy Download .nbib Format: NLM
Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study.

JMIR research protocols

Clemens E, Meijer AJ, Broer L, Langer T, van der Kooi AL, Uitterlinden AG, de Vries A, Kuehni CE, Garrè ML, Kepak T, Kruseova J, Winther JF, Kremer LC, van Dulmen-den Broeder E, Tissing WJ, Rechnitzer C, Kenborg L, Hasle H, Grabow D, Parfitt R, Binder H, Carleton BC, Byrne J, Kaatsch P, Am Zehnhoff-Dinnesen A, Zolk O, van den Heuvel-Eibrink MM.
PMID: 30888333
JMIR Res Protoc. 2019 Mar 19;8(3):e11868. doi: 10.2196/11868.

BACKGROUND: Survival rates after childhood cancer now reach nearly 80% in developed countries. However, treatments that lead to survival and cure can cause serious adverse effects with lifelong negative impacts on survivor quality of life. Hearing impairment is a...

Cite
Clemens E, Meijer AJ, Broer L, et al. Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. JMIR Res Protoc. 2019;8(3):e11868doi: 10.2196/11868.
Clemens, E., Meijer, A. J., Broer, L., Langer, T., van der Kooi, A. L., Uitterlinden, A. G., de Vries, A., Kuehni, C. E., Garrè, M. L., Kepak, T., Kruseova, J., Winther, J. F., Kremer, L. C., van Dulmen-den Broeder, E., Tissing, W. J., Rechnitzer, C., Kenborg, L., Hasle, H., Grabow, D., Parfitt, R., Binder, H., Carleton, B. C., Byrne, J., Kaatsch, P., Am Zehnhoff-Dinnesen, A., Zolk, O., & van den Heuvel-Eibrink, M. M. (2019). Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. JMIR research protocols, 8(3), e11868. https://doi.org/10.2196/11868
Clemens, Eva, et al. "Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study." JMIR research protocols vol. 8,3 (2019): e11868. doi: https://doi.org/10.2196/11868
Clemens E, Meijer AJ, Broer L, Langer T, van der Kooi AL, Uitterlinden AG, de Vries A, Kuehni CE, Garrè ML, Kepak T, Kruseova J, Winther JF, Kremer LC, van Dulmen-den Broeder E, Tissing WJ, Rechnitzer C, Kenborg L, Hasle H, Grabow D, Parfitt R, Binder H, Carleton BC, Byrne J, Kaatsch P, Am Zehnhoff-Dinnesen A, Zolk O, van den Heuvel-Eibrink MM. Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. JMIR Res Protoc. 2019 Mar 19;8(3):e11868. doi: 10.2196/11868. PMID: 30888333; PMCID: PMC6444213.
Copy Download .nbib Format: NLM
Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study.

Cancers

van der Perk MEM, Broer L, Yasui Y, Robison LL, Hudson MM, Laven JSE, van der Pal HJ, Tissing WJE, Versluys B, Bresters D, Kaspers GJL, de Vries ACH, Lambalk CB, Overbeek A, Loonen JJ, Beerendonk CCM, Byrne J, Berger C, Clemens E, Dirksen U, Falck Winther J, Fosså SD, Grabow D, Muraca M, Kaiser M, Kepák T, Kruseova J, Modan-Moses D, Spix C, Zolk O, Kaatsch P, Krijthe JH, Kremer LCM, Brooke RJ, Baedke JL, van Schaik RHN, van den Anker JN, Uitterlinden AG, Bos AME, van Leeuwen FE, van Dulmen-den Broeder E, van der Kooi ALF, van den Heuvel-Eibrink MM, On Behalf Of The PanCareLIFE Consortium.
PMID: 34572825
Cancers (Basel). 2021 Sep 13;13(18). doi: 10.3390/cancers13184598.

CONCLUSIONS: Female CCSs

Cite
van der Perk MEM, Broer L, Yasui Y, et al. Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study. Cancers (Basel). 2021;13(18)doi: 10.3390/cancers13184598.
van der Perk, M. E. M., Broer, L., Yasui, Y., Robison, L. L., Hudson, M. M., Laven, J. S. E., van der Pal, H. J., Tissing, W. J. E., Versluys, B., Bresters, D., Kaspers, G. J. L., de Vries, A. C. H., Lambalk, C. B., Overbeek, A., Loonen, J. J., Beerendonk, C. C. M., Byrne, J., Berger, C., Clemens, E., Dirksen, U., Falck Winther, J., Fosså, S. D., Grabow, D., Muraca, M., Kaiser, M., Kepák, T., Kruseova, J., Modan-Moses, D., Spix, C., Zolk, O., Kaatsch, P., Krijthe, J. H., Kremer, L. C. M., Brooke, R. J., Baedke, J. L., van Schaik, R. H. N., van den Anker, J. N., Uitterlinden, A. G., Bos, A. M. E., van Leeuwen, F. E., van Dulmen-den Broeder, E., van der Kooi, A. L. F., van den Heuvel-Eibrink, M. M., & On Behalf Of The PanCareLIFE Consortium. (2021). Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study. Cancers, 13(18), . https://doi.org/10.3390/cancers13184598
van der Perk, M E Madeleine, et al. "Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study." Cancers vol. 13,18 (2021). doi: https://doi.org/10.3390/cancers13184598
van der Perk MEM, Broer L, Yasui Y, Robison LL, Hudson MM, Laven JSE, van der Pal HJ, Tissing WJE, Versluys B, Bresters D, Kaspers GJL, de Vries ACH, Lambalk CB, Overbeek A, Loonen JJ, Beerendonk CCM, Byrne J, Berger C, Clemens E, Dirksen U, Falck Winther J, Fosså SD, Grabow D, Muraca M, Kaiser M, Kepák T, Kruseova J, Modan-Moses D, Spix C, Zolk O, Kaatsch P, Krijthe JH, Kremer LCM, Brooke RJ, Baedke JL, van Schaik RHN, van den Anker JN, Uitterlinden AG, Bos AME, van Leeuwen FE, van Dulmen-den Broeder E, van der Kooi ALF, van den Heuvel-Eibrink MM, On Behalf Of The PanCareLIFE Consortium. Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study. Cancers (Basel). 2021 Sep 13;13(18). doi: 10.3390/cancers13184598. PMID: 34572825; PMCID: PMC8470074.
Copy Download .nbib Format: NLM
Short fatigue questionnaire: Screening for severe fatigue.

Journal of psychosomatic research

Penson A, van Deuren S, Worm-Smeitink M, Bronkhorst E, van den Hoogen FHJ, van Engelen BGM, Peters M, Bleijenberg G, Vercoulen JH, Blijlevens N, van Dulmen-den Broeder E, Loonen J, Knoop H.
PMID: 32890861
J Psychosom Res. 2020 Aug 28;137:110229. doi: 10.1016/j.jpsychores.2020.110229. Epub 2020 Aug 28.

OBJECTIVE: To determine psychometric properties, a cut-off score for severe fatigue and normative data for the 4-item Short Fatigue Questionnaire (SFQ) derived from the multi-dimensional fatigue questionnaire Checklist Individual Strength (CIS).METHODS: Data of previous studies investigating the prevalence of...

Cite
Penson A, van Deuren S, Worm-Smeitink M, et al. Short fatigue questionnaire: Screening for severe fatigue. J Psychosom Res. 2020;137:110229doi: 10.1016/j.jpsychores.2020.110229.
Penson, A., van Deuren, S., Worm-Smeitink, M., Bronkhorst, E., van den Hoogen, F. H. J., van Engelen, B. G. M., Peters, M., Bleijenberg, G., Vercoulen, J. H., Blijlevens, N., van Dulmen-den Broeder, E., Loonen, J., & Knoop, H. (2020). Short fatigue questionnaire: Screening for severe fatigue. Journal of psychosomatic research, 137110229. https://doi.org/10.1016/j.jpsychores.2020.110229
Penson, Adriaan, et al. "Short fatigue questionnaire: Screening for severe fatigue." Journal of psychosomatic research vol. 137 (2020): 110229. doi: https://doi.org/10.1016/j.jpsychores.2020.110229
Penson A, van Deuren S, Worm-Smeitink M, Bronkhorst E, van den Hoogen FHJ, van Engelen BGM, Peters M, Bleijenberg G, Vercoulen JH, Blijlevens N, van Dulmen-den Broeder E, Loonen J, Knoop H. Short fatigue questionnaire: Screening for severe fatigue. J Psychosom Res. 2020 Aug 28;137:110229. doi: 10.1016/j.jpsychores.2020.110229. Epub 2020 Aug 28. PMID: 32890861.
Copy Download .nbib Format: NLM
Metabolic Syndrome Parameters, Determinants, and Biomarkers in Adult Survivors of Childhood Cancer: Protocol for the Dutch Childhood Cancer Survivor Study on Metabolic Syndrome (Dutch LATER METS).

JMIR research protocols

Pluimakers V, Fiocco M, van Atteveld J, Hobbelink M, Bresters D, Van Dulmen-den Broeder E, Van der Heiden-van der Loo M, Janssens GO, Kremer L, Loonen J, Louwerens M, Van der Pal H, Ronckers C, Van Santen H, Versluys B, De Vries A, Van den Heuvel-Eibrink M, Neggers S.
PMID: 32750002
JMIR Res Protoc. 2021 Jan 27;10(1):e21256. doi: 10.2196/21256.

BACKGROUND: Potential late effects of treatment for childhood cancer include adiposity, insulin resistance, dyslipidemia, and hypertension. These risk factors cluster together as metabolic syndrome and increase the risk for development of diabetes mellitus and cardio- and cerebrovascular disease. Knowledge...

Cite
Pluimakers V, Fiocco M, van Atteveld J, et al. Metabolic Syndrome Parameters, Determinants, and Biomarkers in Adult Survivors of Childhood Cancer: Protocol for the Dutch Childhood Cancer Survivor Study on Metabolic Syndrome (Dutch LATER METS). JMIR Res Protoc. 2021;10(1):e21256doi: 10.2196/21256.
Pluimakers, V., Fiocco, M., van Atteveld, J., Hobbelink, M., Bresters, D., Van Dulmen-den Broeder, E., Van der Heiden-van der Loo, M., Janssens, G. O., Kremer, L., Loonen, J., Louwerens, M., Van der Pal, H., Ronckers, C., Van Santen, H., Versluys, B., De Vries, A., Van den Heuvel-Eibrink, M., & Neggers, S. (2021). Metabolic Syndrome Parameters, Determinants, and Biomarkers in Adult Survivors of Childhood Cancer: Protocol for the Dutch Childhood Cancer Survivor Study on Metabolic Syndrome (Dutch LATER METS). JMIR research protocols, 10(1), e21256. https://doi.org/10.2196/21256
Pluimakers, Vincent, et al. "Metabolic Syndrome Parameters, Determinants, and Biomarkers in Adult Survivors of Childhood Cancer: Protocol for the Dutch Childhood Cancer Survivor Study on Metabolic Syndrome (Dutch LATER METS)." JMIR research protocols vol. 10,1 (2021): e21256. doi: https://doi.org/10.2196/21256
Pluimakers V, Fiocco M, van Atteveld J, Hobbelink M, Bresters D, Van Dulmen-den Broeder E, Van der Heiden-van der Loo M, Janssens GO, Kremer L, Loonen J, Louwerens M, Van der Pal H, Ronckers C, Van Santen H, Versluys B, De Vries A, Van den Heuvel-Eibrink M, Neggers S. Metabolic Syndrome Parameters, Determinants, and Biomarkers in Adult Survivors of Childhood Cancer: Protocol for the Dutch Childhood Cancer Survivor Study on Metabolic Syndrome (Dutch LATER METS). JMIR Res Protoc. 2021 Jan 27;10(1):e21256. doi: 10.2196/21256. PMID: 32750002; PMCID: PMC7875697.
Copy Download .nbib Format: NLM
Health-Related Quality of Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE.

JMIR research protocols

Calaminus G, Baust K, Berger C, Byrne J, Binder H, Casagranda L, Grabow D, Grootenhuis M, Kaatsch P, Kaiser M, Kepak T, Kepáková K, Kremer LCM, Kruseova J, Luks A, Spix C, van den Berg M, van den Heuvel-Eibrink MMM, van Dulmen-den Broeder E, Kuonen R, Sommer G, Kuehni C.
PMID: 33492237
JMIR Res Protoc. 2021 Jan 25;10(1):e21851. doi: 10.2196/21851.

BACKGROUND: Survival after childhood cancer has improved to more than 80% during the last few years, leading to an increased number of childhood cancer survivors. Cancer itself, or its treatment, may cause chronic health conditions, including somatic and mental...

Cite
Calaminus G, Baust K, Berger C, et al. Health-Related Quality of Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE. JMIR Res Protoc. 2021;10(1):e21851doi: 10.2196/21851.
Calaminus, G., Baust, K., Berger, C., Byrne, J., Binder, H., Casagranda, L., Grabow, D., Grootenhuis, M., Kaatsch, P., Kaiser, M., Kepak, T., Kepáková, K., Kremer, L. C. M., Kruseova, J., Luks, A., Spix, C., van den Berg, M., van den Heuvel-Eibrink, M. M. M., van Dulmen-den Broeder, E., Kuonen, R., Sommer, G., & Kuehni, C. (2021). Health-Related Quality of Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE. JMIR research protocols, 10(1), e21851. https://doi.org/10.2196/21851
Calaminus, Gabriele, et al. "Health-Related Quality of Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE." JMIR research protocols vol. 10,1 (2021): e21851. doi: https://doi.org/10.2196/21851
Calaminus G, Baust K, Berger C, Byrne J, Binder H, Casagranda L, Grabow D, Grootenhuis M, Kaatsch P, Kaiser M, Kepak T, Kepáková K, Kremer LCM, Kruseova J, Luks A, Spix C, van den Berg M, van den Heuvel-Eibrink MMM, van Dulmen-den Broeder E, Kuonen R, Sommer G, Kuehni C. Health-Related Quality of Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE. JMIR Res Protoc. 2021 Jan 25;10(1):e21851. doi: 10.2196/21851. PMID: 33492237; PMCID: PMC7870350.
Copy Download .nbib Format: NLM
Increased health-related quality of life impairments of male and female survivors of childhood cancer: DCCSS LATER 2 psycho-oncology study.

Cancer

van Gorp M, van Erp LME, Maas A, Kremer LCM, van Dulmen-den Broeder E, Tissing WJE, Loonen JJ, van der Pal HJH, de Vries ACH, van den Heuvel-Eibrink MM, Ronckers CM, Bresters D, Louwerens M, van der Heiden-van der Loo M, Huizinga GA, Maurice-Stam H, Grootenhuis MA.
PMID: 34726782
Cancer. 2021 Nov 02; doi: 10.1002/cncr.34003. Epub 2021 Nov 02.

BACKGROUND: The objective of this study was to compare the health-related quality of life (HRQOL) of Dutch adult male and female childhood cancer survivors (CCSs) to general population references and to study medical determinants.METHODS: CCSs from the Dutch Childhood...

Cite
van Gorp M, van Erp LME, Maas A, et al. Increased health-related quality of life impairments of male and female survivors of childhood cancer: DCCSS LATER 2 psycho-oncology study. Cancer. 2021;doi: 10.1002/cncr.34003.
van Gorp, M., van Erp, L. M. E., Maas, A., Kremer, L. C. M., van Dulmen-den Broeder, E., Tissing, W. J. E., Loonen, J. J., van der Pal, H. J. H., de Vries, A. C. H., van den Heuvel-Eibrink, M. M., Ronckers, C. M., Bresters, D., Louwerens, M., van der Heiden-van der Loo, M., Huizinga, G. A., Maurice-Stam, H., Grootenhuis, M. A. (2021). Increased health-related quality of life impairments of male and female survivors of childhood cancer: DCCSS LATER 2 psycho-oncology study. Cancer, . https://doi.org/10.1002/cncr.34003
van Gorp, Marloes, et al. "Increased health-related quality of life impairments of male and female survivors of childhood cancer: DCCSS LATER 2 psycho-oncology study." Cancer vol. (2021). doi: https://doi.org/10.1002/cncr.34003
van Gorp M, van Erp LME, Maas A, Kremer LCM, van Dulmen-den Broeder E, Tissing WJE, Loonen JJ, van der Pal HJH, de Vries ACH, van den Heuvel-Eibrink MM, Ronckers CM, Bresters D, Louwerens M, van der Heiden-van der Loo M, Huizinga GA, Maurice-Stam H, Grootenhuis MA. Increased health-related quality of life impairments of male and female survivors of childhood cancer: DCCSS LATER 2 psycho-oncology study. Cancer. 2021 Nov 02; doi: 10.1002/cncr.34003. Epub 2021 Nov 02. PMID: 34726782.
Copy Download .nbib Format: NLM
TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study.

NPJ precision oncology

Meijer AJM, Diepstraten FA, Langer T, Broer L, Domingo IK, Clemens E, Uitterlinden AG, de Vries ACH, van Grotel M, Vermeij WP, Ozinga RA, Binder H, Byrne J, van Dulmen-den Broeder E, Garrè ML, Grabow D, Kaatsch P, Kaiser M, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, Kepakova K, Tissing WJE, van der Kooi ALF, Kremer LCM, Kruseova J, Pluijm SMF, Kuehni CE, van der Pal HJH, Parfitt R, Spix C, Tillmanns A, Deuster D, Matulat P, Calaminus G, Hoetink AE, Elsner S, Gebauer J, Haupt R, Lackner H, Blattmann C, Neggers SJCMM, Rassekh SR, Wright GEB, Brooks B, Nagtegaal AP, Drögemöller BI, Ross CJD, Bhavsar AP, Am Zehnhoff-Dinnesen AG, Carleton BC, Zolk O, van den Heuvel-Eibrink MM.
PMID: 34262104
NPJ Precis Oncol. 2021 Jul 14;5(1):64. doi: 10.1038/s41698-021-00178-z.

In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) approach, we identified a genetic variant in TCERG1L (rs893507) to be associated with hearing loss...

Cite
Meijer AJM, Diepstraten FA, Langer T, et al. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ Precis Oncol. 2021;5(1):64doi: 10.1038/s41698-021-00178-z.
Meijer, A. J. M., Diepstraten, F. A., Langer, T., Broer, L., Domingo, I. K., Clemens, E., Uitterlinden, A. G., de Vries, A. C. H., van Grotel, M., Vermeij, W. P., Ozinga, R. A., Binder, H., Byrne, J., van Dulmen-den Broeder, E., Garrè, M. L., Grabow, D., Kaatsch, P., Kaiser, M., Kenborg, L., Winther, J. F., Rechnitzer, C., Hasle, H., Kepak, T., Kepakova, K., Tissing, W. J. E., van der Kooi, A. L. F., Kremer, L. C. M., Kruseova, J., Pluijm, S. M. F., Kuehni, C. E., van der Pal, H. J. H., Parfitt, R., Spix, C., Tillmanns, A., Deuster, D., Matulat, P., Calaminus, G., Hoetink, A. E., Elsner, S., Gebauer, J., Haupt, R., Lackner, H., Blattmann, C., Neggers, S. J. C. M. M., Rassekh, S. R., Wright, G. E. B., Brooks, B., Nagtegaal, A. P., Drögemöller, B. I., Ross, C. J. D., Bhavsar, A. P., Am Zehnhoff-Dinnesen, A. G., Carleton, B. C., Zolk, O., van den Heuvel-Eibrink, M. M. (2021). TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ precision oncology, 5(1), 64. https://doi.org/10.1038/s41698-021-00178-z
Meijer, A J M, et al. "TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study." NPJ precision oncology vol. 5,1 (2021): 64. doi: https://doi.org/10.1038/s41698-021-00178-z
Meijer AJM, Diepstraten FA, Langer T, Broer L, Domingo IK, Clemens E, Uitterlinden AG, de Vries ACH, van Grotel M, Vermeij WP, Ozinga RA, Binder H, Byrne J, van Dulmen-den Broeder E, Garrè ML, Grabow D, Kaatsch P, Kaiser M, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, Kepakova K, Tissing WJE, van der Kooi ALF, Kremer LCM, Kruseova J, Pluijm SMF, Kuehni CE, van der Pal HJH, Parfitt R, Spix C, Tillmanns A, Deuster D, Matulat P, Calaminus G, Hoetink AE, Elsner S, Gebauer J, Haupt R, Lackner H, Blattmann C, Neggers SJCMM, Rassekh SR, Wright GEB, Brooks B, Nagtegaal AP, Drögemöller BI, Ross CJD, Bhavsar AP, Am Zehnhoff-Dinnesen AG, Carleton BC, Zolk O, van den Heuvel-Eibrink MM. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ Precis Oncol. 2021 Jul 14;5(1):64. doi: 10.1038/s41698-021-00178-z. PMID: 34262104; PMCID: PMC8280110.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 15 entries